Epidermal growth factor receptor tyrosine kinase inhibitors induce CCL2 and CCL5 via reduction in IL-1R2 in keratinocytes

Experimental Dermatology

Volumn 19, Issue 8, 2010, Pages 730-735

  Yamaki, Mayuko ^a   Sugiura, Kazumitsu ^a   Muro, Yoshinao ^a   Shimoyama, Yoshie ^a   Tomita, Yasushi ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

CCL2; CCL5; Epidermal growth factor receptor tyrosine kinase; IL 1; IL 1R2

Indexed keywords

4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; GEFITINIB; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR TYPE II; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES;

ADOLESCENT; ADULT; ARTICLE; CASE REPORT; CONTROLLED STUDY; DRUG EFFECT; DRUG ERUPTION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; KERATINOCYTE; LUNG NON SMALL CELL CANCER; MALE; PROTEIN EXPRESSION; RNA INTERFERENCE;

ACNEIFORM ERUPTIONS; ADOLESCENT; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CASE-CONTROL STUDIES; CELL LINE; ENZYME INHIBITORS; FEMALE; HUMANS; INTERLEUKIN-1; KERATINOCYTES; LUNG NEOPLASMS; MALE; MIDDLE AGED; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, INTERLEUKIN-1; RECEPTORS, INTERLEUKIN-1 TYPE II; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 77954841807     PISSN: 09066705     EISSN: 16000625     Source Type: Journal    
DOI: 10.1111/j.1600-0625.2010.01108.x     Document Type: Article

References (40)

1. Peus D, Hamacher L, Pittelkow M R. EGF-receptor tyrosine kinase inhibition induces keratinocyte growth arrest and terminal differentiation. J Invest Dermatol 1997, 109:751-757.
2. Hansen L A, Woodson R L, Holbus S, Strain K, Lo Y C, Yuspa S H. The epidermal growth factor receptor is required to maintain the proliferative population in the basal compartment of epidermal tumors. Cancer Res 2000, 60:3328-3332.
3. Stoll S, Garner W, Elder J T. Heparin-binding ligands mediate autocrine epidermal growth factor receptor activation in skin organ culture. J Clin Invest 1997, 100:1271-1281.
4. Stoll S W, Benedict M, Mitra R, Hiniker A, Elder J T, Nunez G. EGF receptor signaling inhibits keratinocyte apoptosis: evidence for mediation by Bcl-xL. Oncogene 1998, 16:1493-1499.
5. Nicholson R I, Gee J M, Harper M E. EGFR and cancer prognosis. Eur J Cancer 2001, 37(Suppl. 4):S9-S15.
6. Fukuoka M, Yano S, Giaccone G. Multi institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003, 21:2237-2246.
7. Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 2001, 7:2958-2970.
8. Woodburn J R. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 1999, 82:241-250.
9. Baselga J, Rischin D, Ranson M. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 2002, 20:4292-4302.
10. Robert C, Soria J C, Spatz A. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 2005, 6:491-500.
11. Agero A L, Dusza S W, Benvenuto-Andrade C, Busam K J, Myskowski P, Halpern A C. Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol 2006, 55:657-670.
12. Albanell J, Rojo F, Averbuch S. Pharmacodynamic studies of the epidermal growth factor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 2002, 20:110-124.
13. Yano S, Kondo K, Yamaguchi M. Distribution and function of EGFR in human tissue and the effect of EGFR tyrosine kinase inhibition. Anticancer Res 2003, 23:3639-3650.
14. Kanazawa S, Yamaguchi K, Konoshita Y, Komiyama Y, Muramatsu M, Nomura S. Elevation of soluble interleukin-2 receptor in patients with non-small lung cancer treated with gefitinib. J Cancer Res Clin Oncol 2006, 132:719-725.
15. Sugiura K, Muro Y, Futamura K. The unfolded protein response is activated in differentiating epidermal keratinocytes. J Invest Dermatol 2009, 129:2126-2135.
16. Wakugawa M, Nakamura K, Akatsuka M, Nakagawa H, Tamaki K. Interferon-gamma-induced RANTES production by human keratinocytes is enhanced by IL-1β, TNF-α, IL-4 and IL-13 and is inhibited by dexamethasone and tacrolimus. Dermatology 2001, 202:239-245.
17. Homey B, Dieu-Nosjean M C, Wiesenborn A. Up-regulation of macrophage inflammatory protein-3α/CCL20 and CC chemokine receptor 6 in psoriasis. J Immunol 2000, 164:6621-6632.
18. Zeitvogel J, Werfel T, Wittmann M. Keratinocytes enriched for epidermal stem cells differ in their response to IFN-γ from other proliferative keratinocytes. Exp Dermatol 2008, 17:998-1003.
19. Kupper T S, Ballard D W, Chua A O. Human keratinocytes contain mRNA indistinguishable from monocyte interleukin 1 alpha and beta mRNA. Keratinocyte epidermal cell-derived thymocyte-activating factor is identical to interleukin 1. J Exp Med 1986, 186:2095-2100.
20. Hauser C, Saurat J H, Schmitt A, Jaunin F, Dayer J M. Interleukin 1 is present in normal human epidermis. J Immunol 1986, 9:3317-3323.
21. Mizutani H, Black R, Kupper T S. Human keratinocytes produce but do not process pro-interleukin-1 (IL-1) beta. Different strategies of IL-1 production and processing in monocytes and keratinocytes. J Clin Invest 1991, 87:1066-1071.
22. Kupper T S, Lee F, Birchall N, Clark S, Dower S. Interleukin 1 binds to specific receptors on human keratinocytes and induces granulocyte macrophage colony-stimulating factor mRNA and protein. A potential autocrine role for interleukin 1 in epidermis. J Clin Invest 1988, 82:1787-1792.
23. Groves R W, Sherman L, Mizutani H, Dower S K, Kupper T S. Detection of interleukin-1 receptors in human epidermis. Induction of the type II receptor after organ culture and in psoriasis. Am J Pathol 1994, 145:1048-1056.
24. Dinarello C A. Interleukin-1. Cytokine Growth Factor Rev 1997, 8:253-256.
25. Sims J E, March C J, Cosman D. XcDNA expression cloning of the IL-1 receptor, a member of the immunoglobulin superfamily. Science 1988, 241:585-589.
26. Chen C J, Kono H, Golenbock D, Reed G, Akira S, Rock K L. Identification of a key pathway required for the sterile inflammatory response triggered by dying cells. Nat Med 2007, 13:851-856.
27. McMahan C J, Slack J L, Mosley B. A novel IL-1 receptor, cloned from B cells by mammalian expression, is expressed in many cell types. EMBO J 1991, 10:2821-2832.
28. Colotta F, Re F, Muzio M. Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4. Science 1993, 261:472-475.
29. Lang D, Knop J, Wesche H. The type II IL-1 receptor interacts with the IL-1 receptor accessory protein: a novel mechanism of regulation of IL-1 responsiveness. J Immunol 1998, 161:6871-6877.
30. Bossù P, Visconti U, Ruggiero P. Transfected type II interleukin-1 receptor impairs responsiveness of human keratinocytes to interleukin-1. Am J Pathol 1995, 147:1852-1861.
31. Neumann D, Kollewe C, Martin M U, Boraschi D. The membrane form of the type II IL-1 receptor accounts for inhibitory function. J Immunol 2000, 165:3350-3357.
32. Kuhn P H, Imhof A, Strooper B D. Regulated intramembrane proteolysis of the Interleukin-1 receptor II by a-, b- and g-secretase. J Biol Chem 2007, 282:11982-11995.
33. Okamoto M, Ogawa Y, Watanabe A. Autoantibodies to DFS70/LEDGF are increased in alopecia areata patients. J Autoimmun 2004, 23:257-266.
34. Sugiura K, Muro Y, Nishizawa Y. LEDGF/DFS70, a major autoantigen of atopic dermatitis, is a component of keratohyalin granules. J Invest Dermatol 2007, 127:75-80.
35. Boukamp P, Petrussevska R T, Breitkreutz D, Hornung J, Markham A, Fusenig N E. Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. J Cell Biol 1988, 106:761-771.
36. Uchi H, Terao H, Koga T, Furuse M. Cytokines and chemokines in epidermis. J Dermatol Sci 2000, 24(Suppl. 1):S29-S38.
37. Mascia F, Mariani V, Girolomoni G, Pastore S. Blockage of the EGF receptor induces a deranged chemokine expression in keratinocytes leading to enhanced skin inflammation. Am J Pathol 2003, 163:303-312.
38. Kasper M, Schnidar H, Neill G W. Selective modulation of Hedgehog/GLI target gene expression by epidermal growth factor signaling in human keratinocytes. Mol Cell Biol 2006, 16:6283-6299.
39. Rauschmayr T, Groves R W, Kupper T S. Keratinocyte expression of the type 2 interleukin 1 receptor mediates local and specific inhibition of interleukin 1-mediated inflammation. Proc Natl Acad Sci U S A 1997, 94:5814-5819.
40. Surguladze D, Deevi D, Claros N. Tumor necrosis factor-α ant interleukin-1 antagonists alleviate inflammatory skin changes associated with epidermal growth factor receptor therapy in mice. Cancer Res 2009, 69:5643-5647.